- Abstract viewed - 1025 times
- PDF downloaded - 548 times
License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Affiliations
Iskender Ekinci
Health Sciences University, Kanuni Sultan Suleyman Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Seyma Dumur
Istanbul Atlas University, Faculty of Medicine, Department of Medical Biochemistry, Istanbul, Turkey
Hafize Uzun
Istanbul Atlas University, Faculty of Medicine, Department of Medical Biochemistry, Istanbul, Turkey
Gulden Anataca
Health Sciences University, Kanuni Sultan Suleyman Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Isa Yalcinkaya
Health Sciences University, Kanuni Sultan Suleyman Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Mitat Buyukkaba
Health Sciences University, Kanuni Sultan Suleyman Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Ahmet Cinar
Arnavutkoy State Hospital, Department of Internal Medicine, Istanbul, Turkey
Hanise Ozkan
Health Sciences University, Kanuni Sultan Suleyman Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Irem Kirac Utku
Health Sciences University, Kanuni Sultan Suleyman Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Murat Akarsu
Health Sciences University, Kanuni Sultan Suleyman Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
Omur Tabak
Health Sciences University, Kanuni Sultan Suleyman Training and Research Hospital, Department of Internal Medicine, Istanbul, Turkey
How to Cite
Thrombospondin 1 and Nuclear Factor Kappa B Signaling Pathways in Non-alcoholic Fatty Liver Disease
Abstract
Aim: We aimed to evaluate the circulating thrombospondin-1 (TSP-1) and nuclear factor kappa B (NF-κB) in nonalcoholic fatty liver disease (NAFLD) in order to integrate these signaling pathways in the inflammatory and fibrogenic processes of this liver disorder.
Methods: Ninety-five NAFLD patients were recruited in the study. The study also included 83 age-sex matched healthy controls.
Results: The number of patients with metabolic syndrome (MetS) criteria was 57 (60%). TSP-1 level was found to be statistically significantly lower in the NAFLD group compared to the control group (p=0.037). However, NF-κB level was found to be significantly higher in the NAFLD group compared to the control group (p=0.004). There was a significant negative correlation between plasma TSP-1 levels with glucose (r=-0.235, p=0.022), alanine aminotransferase (r=-0.261, p=0.011) and aspartate transaminase (r=-0.328, p=0.001) levels. In addition, a significant negative correlation was found between plasma TSP-1 and NF-κB levels (r=-0.729, p<0.001).
Conclusions: Our results suggest a close relationship between increased NF-κB and reduced TSP-1 in NAFLD. TSP-1 and NF-κB signaling pathways might have a role in the inflammatory and fibrogenic processes. Furthermore, they may be used as a noninvasive marker and could assist as a therapeutic target for NAFLD.